According to Fox News, a Harvard-led study presented in London and published in JAMA found that the blood biomarker p-tau217 reliably flagged Alzheimer's risk in cognitively healthy older adults. The research tracked nearly 2,700 people with an average age of 70 for up to a decade, showing the test could predict cognitive decline years before memory loss or confusion sets in.
A blood test beats a brain scan on convenience and cost. The harder question is clinical: if doctors can flag risk a decade ahead, families get time to plan and drug trials get better candidates. But what do you actually tell someone who tests positive but feels fine? Early detection only works if there's a clear plan for what happens next.
Alzheimer's care is shifting into the same predictive bucket as cholesterol and genetic risk. People will live for years with a probability instead of a diagnosis. That's useful medicine if regulators, insurers, and doctors build clear rules around it. Without that framework, a powerful blood test becomes an expensive way to give millions of older adults anxiety at 70.
Filed to the Media desk · Jul 18